Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex

Journal of Pediatrics

Volumn 164, Issue 5, 2014, Pages 1195-1200

  Cardamone, Michael ^a,b   Flanagan, Danny ^a,b   Mowat, David ^a,b   Kennedy, Sean E ^a,b   Chopra, Maya ^a   Lawson, John A ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

AML; Angiomyolipoma; Body surface area; BSA; Magnetic resonance imaging; Mammalian target of rapamycin; MRI; mTOR; SEGA; Subependymal giant cell astrocytoma; TSC; Tuberous sclerosis complex

Indexed keywords

CHOLESTEROL; EVEROLIMUS; RAPAMYCIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EPILEPSY; FEMALE; GASTROINTESTINAL SYMPTOM; GINGIVITIS; HUMAN; INTRACTABLE EPILEPSY; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; SIDE EFFECT; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TUBEROUS SCLEROSIS;

ADOLESCENT; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 84899090072     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2013.12.053     Document Type: Article

References (29)

1. G.L. Holmes, and C.E. Stafstrom Tuberous sclerosis complex and epilepsy: recent developments and future challenges Epilepsia 48 2007 617 630
2. D.W. Webb, A.E. Fryer, and J.P. Osborne On the incidence of fits and mental retardation in tuberous sclerosis J Med Genet 28 1991 395 397
3. M.R. Gomez Natural history of cerebral tuberous sclerosis M.R. Gomez, J.R. Sampson, V.H. Whittemore, Tuberous sclerosis complex: Developmental perspectives in psychiatry 1999 Oxford University Press New York 29 46
4. J.H. Cross Neurocutaneous syndromes and epilepsy-issues in diagnosis and management Epilepsia 46 Suppl 10 2005 17 23
5. S. Liang, A. Li, M. Zhao, H. Jiang, S. Yu, and X. Meng et al. Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology Epilepsia 51 2010 2316 2321
6. M. Chopra, J.A. Lawson, M. Wilson, S.E. Kennedy, P. Taylor, and M.F. Buckley et al. An Australian tuberous sclerosis cohort: are surveillance guidelines being met? J Paediatr Child Health 47 2011 711 716
7. D.P. Kingsley, B.E. Kendall, and C.R. Fitz Tuberous sclerosis: a clinicoradiological evaluation of 110 cases with particular reference to atypical presentation Neuroradiology 28 1986 38 46
8. C.W. Shepherd, B. Scheithauer, and M.R. Gomez Brain tumors in tuberous sclerosis Ann NY Acad Sci 615 1991 378 379
9. R. Nabbout, M. Santos, Y. Rolland, O. Delalande, O. Dulac, and C. Chiron Early diagnosis of subependymal giant cell astrocytoma in children with tuberous sclerosis J Neurol Neurosurg Psychiatry 66 1999 370 375
10. F.J. O'Callaghan, C.N. Martyn, S. Renowden, M. Noakes, D. Presdee, and J.P. Osborne Sub-ependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study Arch Dis Child 93 2008 751 754
11. C.W. Shepherd, and M.R. Gomez Mortality in the Mayo Clinic Tuberous Sclerosis Complex Study Ann NY Acad Sci 615 1991 375 377
12. R.W. Byard, P.C. Blumbergs, and R.A. James Mechanisms of unexpected death in tuberous sclerosis J Forensic Sci 48 2003 172 176
13. O. Sancak, M. Nellist, M. Goedbloed, P. Elfferich, C. Wouters, and A. Maat-Kievit et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex Eur J Hum Genet 13 2005 731 741
14. L.H. Zeng, N.R. Rensing, and M. Wong Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway Mol Cell Pharmacol 1 2009 124 129
15. P.B. Crino The pathophysiology of tuberous sclerosis complex Epilepsia 51 Suppl 1 2010 27 29
16. D.N. Franz, J. Leonard, C. Tudor, G. Chuck, M. Care, and G. Sethuraman et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex Ann Neurol 59 2006 490 498
17. D.A. Krueger, M.M. Care, K. Holland, K. Agricola, C. Tudor, and P. Mangeshkar et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
18. J.J. Bissler, F.X. McCormack, L.R. Young, J.M. Elwing, G. Chuck, and J.M. Leonard et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis N Engl J Med 358 2008 140 151
19. E.S. Roach, M.R. Gomez, and H. Northrup Tuberous Sclerosis Consensus Conference: revised clinical diagnostic criteria J Child Neurol 23 2008 1238 1239
20. M. Wong Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies Epilepsia 51 2010 27 36
21. G. Wiegand, T.W. May, P. Ostertag, R. Boor, U. Stephani, and D.N. Franz Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 17 2013 631 638
22. R. Cao, A. Li, and H.Y. Cho mTOR signaling in epileptogenesis: too much of a good thing? J Neurosci 29 2009 12372 12373
23. E. Raffo, A. Coppola, T. Ono, S.W. Briggs, and A.S. Galanopoulou A pulse rapamycin therapy for infantile spasms and associated cognitive decline Neurobiol Dis 43 2011 322 329
24. R. Sindhi, J. Seward, G. Mazariegos, K. Soltys, L. Seward, and A. Smith et al. Replacing calcineurin inhibitors with mTOR inhibitors in children Pediatr Transplant 9 2005 391 397
25. C. Castro, J.M. Campistol, D. Sancho, F. Sanchez-Madrid, E. Casals, and V. Andres Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway Atherosclerosis 172 2004 31 38
26. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, and R. Kuperman et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 2013 125 132
27. D.A. Krueger, A.A. Wilfong, K. Holland-Bouley, A.E. Anderson, K. Agricola, and C. Tudor et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex Ann Neurol 2013 10.1002/ana.23960
28. M. Wong A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials Expert Rev Neurother 13 2013 657 669
29. F.J. Giles The toxicities of modern targeted therapies: learning from the price of progress Target Oncol 4 2009 65 66